Lahav Gil, Chief Executive Officer
Lahav has over 30 years of experience in tech-innovation, design and development. He founded Kangaroo Group (ISO 13485) in 2003, a full-spectrum outsourcing platform for Medical Devices innovation, MedTech commercialization strategies, engineering, design, productization, regulatory submissions and contract manufacturing. Lahav built Kangaroo into a national brand and sold to Starfish Medical in April 2017.
Lahav contributed to over 200 technology product launches and game-changing innovations for Canadian startups, and has lectured at Bzelel Academy of Art and Design in Israel and guest lectured at major universities in Toronto on Innovation Culture, Technology Entrepreneurship, Medical Devices Commercialization and Values-based Leadership
w. Clark kent, president
Clark is a capital markets professional with extensive experience leading corporate development and finance initiatives in the natural resources, technology and life science industries. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace. Clark began his career with a boutique investment firm where he focused on client relations and marketing.
Tom Glawdel, Chief Science Officer
Mr. Glawdel is a decorated PhD in Mechanical and Mechatronics Engineering from the University of Waterloo with experience in the development of microfluidic, molecular diagnostics, RUO products and medical devices both internal and through strategic research partnerships. Tom has authored 30+ academic publications and patent applications.
iGAL Roytblat, chief technology officer
Mr. Roytblat has over 25 years experience as a leader and innovator in the technology sector starting his career as a software developer in the Israeli Electro-Optical industry. Prior to joining ChroMedX iGAL spent over 10 years overseeing software and hardware development as CTO at Kangaroo. Preceding his time at Kangaroo, iGAL served as Chief Software Architect at IMAX corporation, leading the design and development of the MPX product line. iGAL holds a B.Eng. in Electrical Engineering and M.Sc. in Communications and Computer Engineering from the Ben-Gurion University in Israel and is an inventor of numerous patents.
Jessica Kuhn, chief operations officer
Ms. Kuhn has extensive experience managing projects in technology product development. She was formerly COO of Kangaroo group where she worked to implement systems and processes to improve and build stability in Kangaroo’s operations, while managing development projects for key clients. Before that she was Project Manager, Research & Development at Sunwell Technologies where she headed clean-tech development projects with partners from around the world. She holds an MBA from Rotman School of Management, a MASc in Mechanical Engineering and a BASc in Chemical Engineering from the University of Toronto.
Michaela Shaw, Director of Quality Assurance and Regulatory Assurance
Michaela brings over 15 years experience within the medical device industry where she worked with a variety of start-up companies, leading them through the FDA, Health Canada and EU regulatory approval process. Michaela’s experience includes many noteworthy product and device regulatory approvals in the area of medical imaging, cardiovascular and respiratory therapy, medical device software and point-of-care diagnostic devices.
Michaela has provided quality and regulatory assistance to a variety of companies within the IVD, Medical Device, consumer and electronics industries. Previously, she has served as the Quality and Regulatory lead at Kangaroo Design, Thornhill Research Inc. and Z-Tech Canada Inc., where she led these innovative medical device firms through their initial ISO 13485 registration process and obtained EU, FDA and Health Canada approvals for their products. She is a member of the American Society of Quality (ASQ) where she achieved a Certified Manager of Quality (CQM) certification in 2011 and actively maintains her ASQ Certified Biomedical Auditor (CBA) certification.
dr. Richard Janeczko, chief commercial officer
Dr. Janeczko is a 25-year veteran of the in-vitro diagnostics industry, specializing in the marketing and management of molecular assays, proteomics, companion diagnostics, and personalized medicine. He has led multiple diagnostic marketing projects from design and development through regulatory approval and market launch. He is a strong advocate of health economics as the key driver for new technology adoption in a global healthcare reform environment. In 2013, he formed DxEconomix to provide unique IVD marketing services based on system-wide economic impact of diagnostics and value-based pricing. DxEconomix has extensive experience in health economics, clinical sciences, and health technology assessment and adoption in multiple markets including USA, Canada and Europe.
chris Hopkins, chief financial officer
Chris has over 25 years of leadership and financial management experience in the capital markets. He has spent most of his career in senior roles with public mining companies, including U.S. Silver, Rio Algom, BHP Billiton, Suncor and several Canadian and international companies.
He has a Bachelor of Commerce from the University of Toronto, and a Chartered Accountant designation and MBA from the Schulich School of Business at York University.
raj Kailasanathan, executive vP corp finance
Mr. Kailasanathan is a seasoned finance professional with more than 24 years of progressive experience in Asia and North America. Over the last 10 years Raj has served in executive positions for several companies in the MedTech and FinTech sectors.
Prior to joining ChroMedX Corp., Raj was the CFO at Kangaroo Group where he led the finance and accounting functions for the company. His insight, relationship management and negotiating skills assisted in the growth of the company, which eventually lead to its sale in April 2017. Prior to Kangaroo Group Raj was Director of Finance and Corporate Treasurer at the TSX listed company Real Matters Inc.
Raj is committed and passionate about maximizing long-term shareholder value, entrepreneurism, innovation, growth initiatives, and maintaining a high level of integrity and transparency.
Gerard Edwards, executive Chairman
Gerard Edwards holds an undergraduate degree in Commerce and a Masters of Business Administration with a focus in finance. Mr. Edwards has 30 years of independent business experience as a serial entrepreneur and venture capitalist. He has developed companies in the technology sector, oil & gas exploration/development, and real estate development.
John Soloninka, Senior Vice-President, Acquisitions and Exits
John graduated from Queen's University in engineering physics in 1981 and worked several years in aerospace engineering before earning an MBA with distinction, from the University of London in England in 1986.
John has a deep understanding of health systems, reimbursement, health economics and regulatory processes. As a strategy consultant for IBM, Price Waterhouse and Accelerant Health Innovations, he led high impact health system transformation projects, consulted extensively to government and private sector clients and created and led large medical research coalitions in oncology, neuroscience and clinical trials. He understands the divergent needs of academic research, government and public institutions, start-ups, mid-sized private and public companies, including $100B globally-integrated companies with large R&D and patent portfolios.
As designated “Canadian Investment Champion”, John led inter-government and inter-company missions to the EU, USA, Israel, Japan, Singapore, Qatar, Dubai and China, resulting in joint ventures for R&D, commercialization, and “soft landing” market access partnerships in the US, UK, China and Switzerland. John was privileged to be an Expert Witness on Health Innovation for the Canadian Government’s House Standing Committee on Healthcare.
John has recently served on advisory boards and boards of directors for the Centre for Imaging Technology Commercialization (CIMTEC), the Ontario Brain Institute (OBI), HTX, MaRS EXCITE (Excellence in Clinical Innovation and Technology Evaluation), and Baycrest Centre/Rotman Research Institute. He was formerly Chair of the Rotman Research Institute's Research Advisory Committee (RAC).
Yoav Raiter, Director, Product Development
Yoav’s wide-spanning career has focused on developing innovative software and medical device products mainly for start-ups and fast-growing companies. Yoav developed processes to ensure delivery of clients needs at high quality, improved operations, and business strategy.
Prior to joining Relay Medical, Yoav was project manager for strategic accounts at StarFish Medical and Director of project management and business development at Kangaroo Group. Yoav has additionally held several prominent positions managing large scale ERP product development and implementation projects for broadcasters in Canada and the US for Pilat Media and SintecMedia.
Yoav was the co-founder and Co-CEO of Panta-Rhei, a software development and consulting firm. In this position Yoav lead the development of new products and has consulted and worked with a wide variety of companies as instructor for creative thinking methodologies where he helped organizations improve their processes and strategies.
Yoav received an MBA, Specialized in High Tech Innovation Strategy, from Haifa University in Israel and B.Sc., Industrial Engineering, major: Project Management, Business Development and Information Systems from the Technion at Haifa, Israel.
Paul Glavina, Vice President, In Vitro Diagnostics
Paul is a technical and business leader with a record of bringing disruptive, world-class in vitro diagnostics products from concept to the marketplace and ensuring continued market growth and expansion. He was a leader for over 25 years with Abbott Point of Care and its precursor, i-STAT Corporation, designing, developing, manufacturing, and marketing the world’s first handheld blood gas and electrolyte analyzer. He is an inventor with a number of patents and an Abbott Chairman’s Award.
Paul has also been a leader in the broader diagnostics technical and professional community, including as a member of United States Technical Advisory Group to ISO TC 212, an advisor and contributing author to multiple Clinical and Laboratory Standards Institute projects, a member of the Laboratory Working Group, National Kidney Disease Education Program, a member of the CLIA Working Group, Advanced Medical Technology Association (AdvaMed), and a member of the Technical Advisory Committee, Canadian Microelectronics Corporation.